SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise ® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine... Read More

Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies 1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight ®... Read More

SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET. The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday,... Read More

Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test GUILDFORD, SURREY / ACCESS Newswire / August 20, 2025 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it... Read More

SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice... Read More

Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's... Read More

Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds 1 of $9.5 million, revenue increased 5% year-over-year. Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2%... Read More

SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an... Read More

SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update... Read More

SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place... Read More

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGene TM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the... Read More

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRD SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease... Read More

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the... Read More

Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46 th... Read More

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore ® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk... Read More

Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First... Read More

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight ® Mental Health Monitor, a nationwide survey from Myriad Genetics ,... Read More

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business... Read More

SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled... Read More

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the GeneSight ® Psychotropic Test. “Millions of Americans face major depressive disorder... Read More

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million,... Read More

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of... Read More

SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . ( NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi , a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast... Read More

Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.7%, increased 300 basis points year-over-year, benefiting from improving revenue per test trends and greater laboratory efficiencies. Fourth quarter and full-year 2024 GAAP net loss was $(43) million and $(127) million,... Read More

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company’s current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is... Read More

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to... Read More

SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America’s Best Employers 2025 . This prestigious recognition is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. “Working at Myriad Genetics means being part of a dynamic... Read More

SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview... Read More

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life members. The agreement enables more than one million individuals within CancerCARE’s network to assess their... Read More

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, molecular residual disease (MRD) assay to market. US patent No. 12,215,391 relates to Myriad’s... Read More

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris ® Prostate Cancer Test and MyRisk ® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™. This... Read More

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation” study was awarded SMFM’s “Dru... Read More

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing. The “ Know More Sooner ” website provides the benefits and dispels the common myths of prenatal genetic testing, as well as where to get screened and what actions... Read More

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology (also known as The Green Journal) and was highlighted in the... Read More

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial Results The company expects the following: Fourth quarter of... Read More

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm , a nationally renowned sports broadcaster, who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk ® with... Read More

News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT... Read More

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s... Read More

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc . today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and... Read More

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer Test with RiskScore ® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine . The study was selected by the Genomic Medicine Working Group at the National Human... Read More

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication of its updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange... Read More

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective immediately, expanding the Board from eight to nine members. Additionally, Davis was also appointed to the Audit and Finance Committee of Myriad’s Board. Davis is the Senior Relationship and Growth Advisor for... Read More

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network (NCCN ® ) as the guidelines underscore the critical role of the company’s portfolio of offerings across the patient’s prostate cancer journey. These guidelines further validate Myriad’s ability to... Read More

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium ® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries. Additional new data will show how Myriad’s second-generation... Read More

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network (NCCN ® ) as an ‘Advanced Tool’ in the fight against prostate cancer 1 . Like other gene expression-based tests, Prolaris for many years has been... Read More

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed... Read More

SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. “Previously, I would schedule my patients to come... Read More

SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek , the #1 OBGYN-recommended gender test with over 99% accuracy, [1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on... Read More

Highlights Third quarter revenue grew 11% year-over-year to $213 million , driven by Pharmacogenomics ( 34% ) and Prenatal ( 10% ) and progress on payor coverage and revenue cycle initiatives. Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA... Read More

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange benefit plans, effective January 1 st , 2025. After... Read More

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventative genetic testing with a focus on high-risk populations. The collaboration combines the strengths of Myriad’s high-quality hereditary cancer and reproductive... Read More

Myriad’s MyRisk ® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR ® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health , a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows... Read More

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise ® MRD test. Research collaborations include: A study to determine whether circulating tumor DNA (ctDNA) level may predict... Read More

SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima’s UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad’s ability to... Read More

SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent no. 12,104,212, entitled “Personalized Methods for... Read More

SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies highlighting its advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 43 rd Annual Conference, which will take place from Sept. 17-21, 2024, in New Orleans, LA. The research will... Read More

SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central Hotel in New York City on October 9, 2024. The in-person event will commence at 9:00 am EDT and last approximately two hours. Paul J. Diaz, President and CEO, and other members of the Myriad executive leadership team will discuss... Read More

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences. The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET. The Morgan Stanley Healthcare Conference in a... Read More

Highlights Second quarter revenue grew 15% year-over-year to $212 million , driven by Prenatal ( 25% ), Pharmacogenomics ( 22% ), and Hereditary Cancer ( 19% ). Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023. Increasing 2024 financial guidance with full year revenue moving to a... Read More

SALT LAKE CITY, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it completed the sale of its EndoPredict ® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences. As part of the sale, Myriad also licensed Eurobio the right to sell Prolaris ® in vitro diagnostic kits outside of the... Read More

SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both... Read More

SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition , which revealed that a majority (63%) of women do not know that there is an increased risk of breast cancer for women with dense breasts. The survey, now in its third year , focused on understanding... Read More

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in... Read More

SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent no. 12,024,749, entitled “Combinatorial DNA... Read More

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it’s a Great Place To Work – 27 percentage... Read More

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight ® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics , Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. “The results of the Special Election Survey show that politics and elections... Read More

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests... Read More

SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight ® Carrier Screen . The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions. The conditions added to the Universal Plus panel were named in the American College of... Read More

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine , an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore ® , Myriad’s breast cancer risk assessment tool integrated into its MyRisk ® Hereditary Cancer Test. RiskScore... Read More

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice ® CDx HRD... Read More

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy 1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding... Read More

Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal ( 22% ), Pharmacogenomics ( 21% ), and Hereditary Cancer ( 16% ). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts. First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million ; net loss and adjusted EBITDA improved significantly from $55... Read More

SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States. As part of the reorganization, Myriad signed a definitive agreement to... Read More

SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s... Read More

SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad... Read More

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study 1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel ® , which incorporates fetal fraction amplification. Prior... Read More

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight ® Psychotropic test . “We are encouraged by the initial results of this study that showed how... Read More

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers... Read More

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm , provides... Read More

Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek ® volume. Full-year 2023 revenue of $753 million , grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek), Prolaris (21%), Pharmacogenomics (9%), and Hereditary Cancer (7%). Fourth quarter GAAP operating expenses of $166 million and adjusted operating expenses of $130 million , each down 6% year-over-year. Fourth quarter GAAP cash... Read More

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad’s ultra-sensitive MRD test, Precise MRD, to... Read More

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her... Read More

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s... Read More

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology... Read More

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise... Read More

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer. The new guideline offers multi-pronged, evidence-based clinical practice recommendations. Among the... Read More

SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST. The presentation will be available through a live webcast in the investor relations section of Myriad’s... Read More

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. Riggsbee will continue as a strategic advisor through March 31, 2024, to ensure a smooth transition. Riggsbee... Read More

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients. The latest... Read More

SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek ® Early Gender DNA Test . Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy. SneakPeek is... Read More

SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. , a leader in advanced genomics for precision oncology, (Nasdaq: PSNL) today announced a non-exclusive collaboration through which Myriad will market the Personalis ® ImmunoID NeXT ultra-comprehensive biomarker discovery platform to its... Read More

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in the Stephens Annual Investment Conference in Nashville, TN with a fireside chat on Wednesday, November 15 at 2:00 p.m. ET. A live and archived webcast of the presentation can be viewed in the investor relations section of Myriad’s... Read More

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced the pricing of an upsized underwritten public offering of 6,470,588 shares of its common stock, par value $0.01 per share (“common stock”), at a public offering price of $17.00 per share for expected gross proceeds of approximately... Read More

SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad Genetics”), a leader in genetic testing and precision medicine, today announced that it plans to make a public offering of $100.0 million of shares of its common stock, par value $0.01 per share (“common stock”), in an underwritten registered public offering. The Company also expects to grant the underwriters a... Read More

Highlights: Third quarter testing volume grew 18% year-over-year, excluding contributions from the SneakPeek ® Early Gender DNA Test, the fifth consecutive quarter of double-digit year-over-year growth. In the third quarter and year-to-date: Hereditary cancer test volumes grew 18% and 20% year-over-year, respectively. GeneSight ® pharmacogenomics test volumes grew 19% and 24% year-over-year, respectively. Prenatal test... Read More

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023. Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in life sciences and molecular diagnostics, to the team at Myriad... Read More

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests C ombined strengths in assay development, clinical testing, and regulatory approvals offers pharma partners comprehensive global companion diagnostic solutions based on PCR, digital PCR (using the QIAcuity system), and NGS Future projects may include advanced analysis and accessibility of measurable residual disease (MRD)... Read More

SALT LAKE CITY , Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc. , (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors. Experience the full interactive Multichannel News Release here:... Read More

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health history are two misunderstood breast cancer risk factors. The Myriad Genetics Cancer Risk Survey found that nearly half (48%) of the women surveyed do not know what breast density is, and 50%... Read More

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted therapies. Under the strategic partnership, Myriad and... Read More

SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report , highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, we understand the important role we... Read More

SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study the use of minimal residual disease (MRD) testing in breast cancer. The research project will use Myriad’s MRD testing platform, a tumor-informed high-definition assay that uses whole-genome... Read More

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work ® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List . The highly competitive list is based on the analysis of survey responses from over 208,000 employees from Great Place To Work Certified™... Read More

SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating widespread confusion and misconceptions about ovarian cancer screening among a majority of women. The Myriad Genetics Cancer Risk survey shows that nearly three out of four women (71%) falsely believe annual pap smears include... Read More

SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the Morgan Stanley 21 st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT. On Sept. 19, Myriad will host an in-person Investor Day at the newly constructed Dr. Walter Gilbert... Read More

SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health , a leading national provider of breast health services, today announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk. The collaboration combines the strengths of Myriad’s hereditary breast... Read More

SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco on September 19, 2023. The in-person event will commence with a facility tour beginning at 9:00 am PDT. The Investor Day presentation and Q&A will take place from 10:00 am to... Read More

Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy 1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction (ARR) into the Prolaris ® Prostate Cancer Prognostic Test to help patients and providers make... Read More

SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the Intermountain Health system, will begin providing oncology test results that allow access to the ComboMATCH trials. ComboMATCH is a coordinated platform of clinical oncology trials sponsored by the National Cancer Institute (NCI), part of... Read More

SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight ® Psychotropic test, a pharmacogenomic test for mental health medications. The GeneSight report will now include information on how a patient's smoking status may impact their body's metabolism of certain medications. Many factors may influence... Read More

Highlights: Second quarter testing volume grew 17% year-over-year , excluding contributions from the SneakPeek ® Early Gender DNA Test. In the second quarter: Hereditary cancer test volumes grew 20% year-over-year, the third consecutive quarter of double-digit growth year-over-year. GeneSight ® pharmacogenomics test volumes grew 23% year-over-year. Prenatal test volumes grew 12% year-over-year, excluding contributions from... Read More

SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit from a change in their breast care SALT LAKE CITY, July 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its MyRisk ® Hereditary Cancer Test... Read More

SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million asset-based credit facility (the “ABL Facility”) with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, and the other lender parties thereto consisting of Wells Fargo Bank, N.A. and Bank of America, N.A. The... Read More

SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response. The project will use Myriad’s minimal residual disease (MRD) testing platform, a tumor-informed... Read More

SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will participate in the 44 th Annual Goldman Sachs Global Healthcare Conference with a fireside chat on Tuesday, June 13, 2023 at 2:00 p.m. PT. A replay of the fireside chat will be available on the investor relations section of Myriad’s... Read More

SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Myriad has recently made several advancements supporting its oncology footprint including... Read More

SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit. In his new role, Dr. Brufsky is responsible for guiding clinical development and medical affairs to further elevate Myriad’s Precise™ Oncology Solutions portfolio. “Adam is an... Read More

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE ® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers... Read More

SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work ® certification for 2023. The certification is based solely on what current employees say about their experience working at Myriad. This year, 86% of Myriad employees said the company is a great place to work – 29 percentage points... Read More

Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek ® Early Gender DNA Test. In the first quarter: Hereditary cancer test volumes grew 24% year-over-yea r, the second consecutive quarter of double-digit growth year-over-year. Hereditary cancer test volumes in Women's Health grew 32% year-over-year. GeneSight ® pharmacogenomics test volumes grew... Read More

SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, NV. Myriad management will participate in a fireside chat on Tuesday, May 9 at 3:00 p.m. PT. A live and archived webcast of the presentation can be viewed in the investor... Read More

SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

SALT LAKE CITY, April 19, 2023 (GLOBE NEWSWIRE) -- From restricted or binge eating to excessive gambling to extreme social media use, 77% of Americans surveyed say they have used at least one addictive behavior and/or unhealthy coping mechanism to manage their mental health issues, according to the GeneSight ® Mental Health... Read More

SALT LAKE CITY, April 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This achievement follows a recent site inspection as part of the New... Read More

SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed ® Imaging , one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States, today announced the planned launch of a new hereditary cancer assessment program that combines diagnostic imaging, genetic risk... Read More

SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling. NSGC’s guidelines support equitable... Read More

Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek ® Early Gender DNA Test. GeneSight, the company's pharmacogenomics test, grew revenue 36% for the full year 2022. Gross margin for the fourth quarter was approximately 70% r eflecting underlying price stability and disciplined cost management.... Read More

SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on Tuesday, Feb. 28, 2023 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the... Read More

SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences. The BTIG MedTech, Digital Health, Life Sciences and Diagnostic Tools Conference on Feb. 14, 2023. The 44 th Annual Raymond James & Associates Institutional Investors Conference with a presentation on... Read More

SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company’s commitment to making genetic testing more accessible and equitable for all patient populations. To advance precision medicine, Myriad is dedicated to ongoing research and has published evidence demonstrating... Read More

Myriad Genetics continues to advance non-invasive prenatal screening with Prequel ® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the... Read More

SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41 st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available through a... Read More

New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution. Marc Leighton recently... Read More

Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a... Read More